Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
120 participants
Study Classification
OBSERVATIONAL
Study Start Date
2021-06-17
Study Completion Date
2022-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with scheduled in-office examinations at Week 1, Week 5 and Interim Visits, when applicable, with additional in-office Cirrus volume scans acquired at these office visits. The self-imaging data on the NVHO will be automatically uploaded to the Notal Health Cloud and from there the reconstructed volume scans will sent to the study database.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD
NCT05650047
Retinal Neovascularization
UNKNOWN
Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
NCT04650672
Retinal Neovascularization
COMPLETED
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
NCT05281042
Neovascular Age-related Macular Degeneration
COMPLETED
Single In-Clinic Encounter With the Notal Vision Home OCT
NCT04642183
Neovascular Age-related Macular Degeneration
Intermediate Age Related Macular Degeneration (Disorder)
COMPLETED
The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT
NCT05202587
Neovascular Age-related Macular Degeneration
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objectives of this study are to (1) evaluate the agreement, via positive percent agreement (PPA) and negative percent agreement (NPA), between OCT images captured by the NVHO and by the Zeiss Cirrus HD-OCT in the visualization of fluid as identified by a RC, in the central 10 degrees of the macula of NV-AMD patients, and (2) evaluate the ability of subjects diagnosed with NV-AMD to set up the device and self-image their eyes at home with the NVHO device (rate of successful imaging attempts).Description of Study Visits and Procedures:
Enrollment Visit:
At this visit, the exams will be conducted in the following order:
1. Subject will be informed concerning the study and sign the Informed Consent Form (ICF) prior to the conduct of any study procedures.
2. The following data will be collected for each study subject:
1. Subject's date of birth (DOB) (if allowed) or age
2. Gender
3. Race
4. Ethnicity
5. Level of education
3. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma), will be performed on both eyes on the day of the visit.
4. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mm X 6mm, 512 X 128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
5. One or both eye(s) of the subject that meets all screening criteria, including having a diagnosis of NV-AMD in at least one eye previously or at the enrolment visit, will be enrolled in the study.
* Subjects who do not meet all screening criteria will be deemed a screen failure and will be exited from the study.
* Study eyes enrolled with fluid in the primary study eye, may receive treatment during the Week 1 Visit.
* If in the investigator's opinion, the treatment cannot be delayed by approximately 7 days until the Week 1 visit, the subject will be exited from the study as a Screen Failure.
NOTE: For the subjects with both eyes with NV-AMD, one eye will be randomly selected as the primary eye during enrollment and the other will be the secondary eye. For subjects with only one eye with NV-AMD, the fellow eye with dry AMD may be enrolled. For such subjects, the NV-AMD eye will be the primary eye and the other eye will be the secondary eye.
6. The following data will be collected for the study eye:
1. Qualifying diagnosis for the study eye from the subject's medical record
2. From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:
i. Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings
7. The subject will receive a general overview (including a description of the device and a review of the NVHO set-up guide) of the self-operation of the NVHO device at the investigational clinic facility by trained study personnel.
8. The subject will be (1) reminded that the NVHO device will be delivered to their home and (2) instructed to self-image the study eye(s) once daily using a NVHO device at home for 5 weeks and the Week 1 and Week 5 visits will be scheduled.
9. Collect AEs, if applicable.
Home Set-up with Remote Assistance (NVHO Setup Period)
Following confirmation of subject eligibility at the Enrollment Visit and the subject is enrolled in the study:
1. The subject will be contacted by the NVDC to verify their delivery address.
2. The device will be delivered to the subject's home, with confirmation sent back to the NVDC.
3. Remote support is available by the Notal Vision Diagnostic Clinic (NVDC) via phone during normal business hours, if needed.
4. The subject will follow the steps detailed in the Set-up Guide included in the box. This is considered NVHO Setup Period.
Note: A care giver, family member or friend is allowed to assist. At most four additional calibrations can be performed, on the same day or different consecutive days, for each study eye if the calibration is not successful.
Note: If an eye cannot calibrate during 5 separate attempts, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
5. Collect AEs, if applicable.
In-Home Phase (Day 1 to Day 35 post NVHO Setup Period) Following set-up of the NVHO,
1. Day 1: The subject will perform the first self-imaging session with the NVHO device on both eyes followed by automated transmission of the scans. This first session will be considered a practice session.
2. Days 2-35: The subject will perform one self-imaging session each day on the study eye(s) with the NVHO device followed by automated transmission. Each scan has a reliability score provided by the NVHO.
Note: If an eye fails to self-image five consecutive times, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
3. Collect AEs, if applicable, as reported by telephone call or office visit to the investigational site.
Week 1 (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit one week after the NVHO Setup Period (Home Set-up). The sponsor will provide transportation upon request. At this visit, the exams will be conducted in the following order:
1. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
2. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
3. Initiate standard of care and treatment, if necessary.
4. Collect AEs, if applicable. Week 5 / Exit (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit five weeks after the NVHO Setup Period (Home Set-up). At this visit, the exams will be conducted in the following order:
1. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
2. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
3. Initiate standard of care and treatment, if necessary.
4. Collect AEs, if applicable.
5. Exit subject from the study.
Enrollment Visit:
At this visit, the exams will be conducted in the following order:
1. Subject will be informed concerning the study and sign the Informed Consent Form (ICF) prior to the conduct of any study procedures.
2. The following data will be collected for each study subject:
1. Subject's date of birth (DOB) (if allowed) or age
2. Gender
3. Race
4. Ethnicity
5. Level of education
3. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma), will be performed on both eyes on the day of the visit.
4. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mm X 6mm, 512 X 128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
5. One or both eye(s) of the subject that meets all screening criteria, including having a diagnosis of NV-AMD in at least one eye previously or at the enrolment visit, will be enrolled in the study.
* Subjects who do not meet all screening criteria will be deemed a screen failure and will be exited from the study.
* Study eyes enrolled with fluid in the primary study eye, may receive treatment during the Week 1 Visit.
* If in the investigator's opinion, the treatment cannot be delayed by approximately 7 days until the Week 1 visit, the subject will be exited from the study as a Screen Failure.
NOTE: For the subjects with both eyes with NV-AMD, one eye will be randomly selected as the primary eye during enrollment and the other will be the secondary eye. For subjects with only one eye with NV-AMD, the fellow eye with dry AMD may be enrolled. For such subjects, the NV-AMD eye will be the primary eye and the other eye will be the secondary eye.
6. The following data will be collected for the study eye:
1. Qualifying diagnosis for the study eye from the subject's medical record
2. From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:
i. Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings
7. The subject will receive a general overview (including a description of the device and a review of the NVHO set-up guide) of the self-operation of the NVHO device at the investigational clinic facility by trained study personnel.
8. The subject will be (1) reminded that the NVHO device will be delivered to their home and (2) instructed to self-image the study eye(s) once daily using a NVHO device at home for 5 weeks and the Week 1 and Week 5 visits will be scheduled.
9. Collect AEs, if applicable.
Home Set-up with Remote Assistance (NVHO Setup Period)
Following confirmation of subject eligibility at the Enrollment Visit and the subject is enrolled in the study:
1. The subject will be contacted by the NVDC to verify their delivery address.
2. The device will be delivered to the subject's home, with confirmation sent back to the NVDC.
3. Remote support is available by the Notal Vision Diagnostic Clinic (NVDC) via phone during normal business hours, if needed.
4. The subject will follow the steps detailed in the Set-up Guide included in the box. This is considered NVHO Setup Period.
Note: A care giver, family member or friend is allowed to assist. At most four additional calibrations can be performed, on the same day or different consecutive days, for each study eye if the calibration is not successful.
Note: If an eye cannot calibrate during 5 separate attempts, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
5. Collect AEs, if applicable.
In-Home Phase (Day 1 to Day 35 post NVHO Setup Period) Following set-up of the NVHO,
1. Day 1: The subject will perform the first self-imaging session with the NVHO device on both eyes followed by automated transmission of the scans. This first session will be considered a practice session.
2. Days 2-35: The subject will perform one self-imaging session each day on the study eye(s) with the NVHO device followed by automated transmission. Each scan has a reliability score provided by the NVHO.
Note: If an eye fails to self-image five consecutive times, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
3. Collect AEs, if applicable, as reported by telephone call or office visit to the investigational site.
Week 1 (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit one week after the NVHO Setup Period (Home Set-up). The sponsor will provide transportation upon request. At this visit, the exams will be conducted in the following order:
1. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
2. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
3. Initiate standard of care and treatment, if necessary.
4. Collect AEs, if applicable. Week 5 / Exit (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit five weeks after the NVHO Setup Period (Home Set-up). At this visit, the exams will be conducted in the following order:
1. Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
2. Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
3. Initiate standard of care and treatment, if necessary.
4. Collect AEs, if applicable.
5. Exit subject from the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neovascular Age-related Macular Degeneration
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects must have the ability to speak, read and understand English.
2. Ability to understand and agree to contents of informed consent either in writing or verbally.
3. Age 55 or older at the Enrollment Visit.
4. Adults diagnosed with NV-AMD in at least one eye based on the subject's medical record. Fellow eyes diagnosed with dry AMD may be included as secondary eyes to a primary eye diagnosed with NV-AMD.
Note: eyes whit other pathologies including pseudocysts, outer retinal tabulations, pigments epithelial, detachments, hemorrhage, sub retinal hyper reflective material (SHRM), geographic atrophy and sub RPE, hypo reflective areas can be enrolled.
5. Best corrected Visual Acuity of 20/320 or better in eyes that will perform self-imaging.
6. Available and willing to set up a device and conduct self-imaging at their home.
2. Ability to understand and agree to contents of informed consent either in writing or verbally.
3. Age 55 or older at the Enrollment Visit.
4. Adults diagnosed with NV-AMD in at least one eye based on the subject's medical record. Fellow eyes diagnosed with dry AMD may be included as secondary eyes to a primary eye diagnosed with NV-AMD.
Note: eyes whit other pathologies including pseudocysts, outer retinal tabulations, pigments epithelial, detachments, hemorrhage, sub retinal hyper reflective material (SHRM), geographic atrophy and sub RPE, hypo reflective areas can be enrolled.
5. Best corrected Visual Acuity of 20/320 or better in eyes that will perform self-imaging.
6. Available and willing to set up a device and conduct self-imaging at their home.
Exclusion Criteria
1. Anti-VEGF treatment for NV-AMD in the study eye(s) at the screening visit.
2. Any other retinal disease requiring steroidal or anti-VEGF injections.
3. Prior experience with the NVHO device.
2. Any other retinal disease requiring steroidal or anti-VEGF injections.
3. Prior experience with the NVHO device.
Minimum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Notal Vision Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gidi Benyamini, MD
Role: STUDY_DIRECTOR
Druyanov 5, Tel Aviv Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Georgia Retina
Marietta, Georgia, United States
Site Status
RECRUITING
Retina Associates of Kentucky
Lexington, Kentucky, United States
Site Status
RECRUITING
Elman Retina Group, P.A.
Glen Burnie, Maryland, United States
Site Status
RECRUITING
Ophthalmic Cons. of Boston
Boston, Massachusetts, United States
Site Status
RECRUITING
Pepose Vision Institute/Midwest Vision Research Foundation
Chesterfield, Missouri, United States
Site Status
RECRUITING
Wagner Macula & Retina Center
Norfolk, Virginia, United States
Site Status
RECRUITING
Virginia Eye Institute
Richmond, Virginia, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C2021.001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
RECRUITING
PHASE3
Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration
NCT01334294
COMPLETED
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT
NCT05745116
UNKNOWN
Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)
NCT00417846
COMPLETED
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
NCT01103505
COMPLETED
NA
Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
NCT01073592
COMPLETED
Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
NCT01336907
WITHDRAWN
Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients
NCT05417152
COMPLETED
ForeseeHome NRich Registry
NCT05690880
ACTIVE_NOT_RECRUITING
Adaptive Optics Retinal Imaging
NCT02317328
RECRUITING
The Optical Coherence Tomography in Age-Related Macular Degeneration Study: The OCT in AMD Study
NCT00531141
COMPLETED
Adaptive Optics Retinal Imaging
NCT05370287
RECRUITING
NA
Home Retinal Imaging Using NOTAL-OCT V3.0
NCT04241198
COMPLETED
Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies
NCT00408720
COMPLETED
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
NCT00884637
COMPLETED
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
NCT01692938
COMPLETED
Non Exudative AMD Imaged With SS-OCT- Extension
NCT04469140
UNKNOWN
The Impact of Two Strategies in the Monitoring of Exudative ARMD on the Visual Acuity (by OCT B Scan or OCT Angiography)
NCT02868086
COMPLETED
NA
OCT Angiography in Wet AMD
NCT02253030
RECRUITING
OCT Agreement and Precision Study
NCT02045823
COMPLETED
NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients
NCT03969303
COMPLETED
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
NCT00748384
COMPLETED
Agreement and Precision Study of the Nidek Mirante
NCT04318132
COMPLETED
NA